XORTX Therapeutics Inc.

XRTX.V

$2.84+$0.00 +0.00%At close · July 31

Price1Y range $2.43 – $7.50

Valuations

Estimation history is only available for connected users.

Financial Ratios

vs. 4-yr trend

RATIO TREND TTM

Return on Equity Ratios

'23 → TTM

-98.00%

Return on Asset Ratios

'23 → TTM

-46.84%

Growth

There is no growth data currently available.

Ask about XRTX.V

Ask the documents

No research uploaded for this stock yet. Check back later.

Key stats

Return on equity -98.0%

Profile

Sector Health Care

Industry Pharmaceuticals, Biotechnology & Life Sciences

Country Canada

Exchange TSX-V

Website Visit site

About

XORTX Therapeutics Inc. is a Canadian late-stage clinical pharmaceutical company focused on developing therapies that modulate uric acid pathways to treat kidney diseases and metabolic conditions. Its pipeline includes XRx-026 (Phase 3) for gout, XRx-008 (Phase 2) for autosomal dominant polycystic kidney disease, and XRx-101 (Phase 2) for acute kidney injury associated with respiratory virus infection. The company is headquartered in Calgary, Alberta.